NCT06901336View on ClinicalTrials.gov

A Study of LY4064809 [14C]-STX-478 in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

March 20, 2025

Primary Completion Date

May 6, 2025

Study Completion Date

May 6, 2025

Conditions

Healthy

Interventions

DRUG

[14C]-STX-478

oral administration

Trial Locations (1)

42374

Pharmaron Clinical Pharmacology Center Inc, Baltimore

All Listed Sponsors

lead

Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company

INDUSTRY